Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial | Synapse
March 3, 2026
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial
Puntos clave
The fixed-dose regimen effectively maintains virologic suppression in HIV-1 patients after 48 weeks.
Participants showed comparable viral load levels, with 82% remaining virologically suppressed at week 48.
Randomized controlled trial evaluating the non-inferiority of the new treatment against standard therapy.
Findings support the potential for a simpler treatment regimen with improved adherence in HIV care.